1-Phenylcyclohexa-2,4-diene-1-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Phenylcyclohexa-2,4-diene-1-carboxamide
• 英文别名: 1-phenylcyclohexa-2,4-diene-1-carboxamide
• 化学式: C₁₃H₁₃NO
• 分子量: 199.25
• InChiKey: XRQSYBPUBMQFEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE, ET COMPOSITIONS ET MÉTHODES D'UTILISATION DE CEUX-CI
  申请人：CHDI FOUNDATION INC

  公开号：WO2014159218A1

  公开（公告）日：2014-10-02

  Provided are certain histone deacetylase (HDAC) inhibitors of Formula (I), compositions thereof, and methods of their use.

  提供了某些Formula (I)的组织脱乙酰酶（HDAC）抑制剂，其组成物和使用方法。
• NEW METHODS
  申请人：Aeromics LLC

  公开号：EP2846787A2

  公开（公告）日：2015-03-18
• HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS
  申请人：CHDI Foundation, Inc.

  公开号：EP2968207A1

  公开（公告）日：2016-01-20
• NOVEL METHODS
  申请人：Aeromics, Inc.

  公开号：EP3065728A1

  公开（公告）日：2016-09-14
• [EN] NEW METHODS<br/>[FR] NOUVEAUX PROCÉDÉS
  申请人：AEROMICS LLC

  公开号：WO2013169939A2

  公开（公告）日：2013-11-14

  The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.